This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

UnitedHealth Beans Quest Diagnostics

Updated from Oct. 3

UnitedHealth (UNH - Get Report) sure knows how to play hardball.

Just ask Quest Diagnostics (DGX - Get Report), the largest provider of clinical lab services in the country. This week, Quest lost out on a national contract with UnitedHealth -- a company that accounts for 7% of its revenue -- because, it said, "the terms and conditions that were offered by UnitedHealth would have been irresponsible for us to accept."

Competing LabCorp (LH - Get Report) felt differently and scooped up the 10-year, $3 billion contract for itself.

For Quest, which was favored by experts to land the huge deal, the news brought immediate pain. The company's shares plummeted 11% to $54.02. In comparison, LabCorp looked like a big winner with its stock up 3.5% to $67.50.

Meanwhile, UnitedHealth itself was up fractionally as the company went about doing its business of driving hard bargains and impressing Wall Street.

"UnitedHealth promised in their last investor day that they were going to get $300 million worth of medical cost savings over time," notes Sheryl Skolnick, senior vice president of CRT Capital group. "That comes from hospitals, physicians, labs -- you name it. This is just one step in that direction."

At this point, UnitedHealth seems compelled to step all over any party that tries to stand in its away. Recently, for example, UnitedHealth refused to pay higher rates to some HCA (HCA - Get Report) hospitals even though those facilities have become "out-of-network" -- pushing UnitedHealth policyholders elsewhere -- as a result. Meanwhile, the company has slashed its payments to giant institutional pharmacy operator Omnicare (OCR) as well.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
DGX $75.39 -0.85%
HCA $81.51 -0.35%
LH $118.32 -0.50%
UNH $117.89 -1.40%
AAPL $130.15 -1.20%

Markets

DOW 17,977.35 -148.77 -0.82%
S&P 500 2,113.06 -7.73 -0.36%
NASDAQ 5,078.5520 -19.4240 -0.38%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs